An Act To Require Health Insurance Coverage For Biomarker Testing
Maine bill mandates health insurance coverage for biomarker testing to improve disease detection, now pending budget review before final enactment.
Maine bill mandates health insurance coverage for biomarker testing to improve disease detection, now pending budget review before final enactment.
LD 107 requires health insurance plans in Maine to cover biomarker testing—diagnostic tests that identify biological markers indicating disease risk, presence, or prognosis. The bill passed both chambers and was placed on the Special Appropriations Table, meaning it requires budget review before final enactment due to potential state fiscal impacts.
Biomarker testing can enable early disease detection and personalized treatment decisions, potentially improving health outcomes and reducing long-term medical costs. However, mandating insurance coverage creates new financial obligations for insurers and may affect premium costs, making this a healthcare access versus affordability tradeoff with real budgetary consequences for the state.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.